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Abstract
Antipseudomonal carbapenems have played a useful role in our
antimicrobial armamentarium for 20 years. However, a review of
their use during that period creates concern that their clinical
effectiveness is critically dependent on attainment of an appro-
priate dosing range. Unfortunately, adequate carbapenem dosing
is missed for many reasons, including benefit/risk misconceptions,
a narrow therapeutic window for imipenem and meropenem (due
to an increased rate of seizures at higher doses), increasingly
resistant pathogens requiring higher doses than are typically given,
and cost containment issues that may limit their use. To improve
the use of carbapenems, several initiatives should be considered:
increase awareness about appropriate treatment with carbapenems
across hospital departments; determine optimal dosing regimens
for settings where multidrug resistant organisms are more likely
encountered; use of, or combination with, an alternative anti-
microbial agent having more favorable pharmacokinetic, pharmaco-
dynamic, or adverse event profile; and administer a newer
carbapenem with lower propensity for resistance development (for
example, reduced expression of efflux pumps or greater stability
against carbapenemases).
Introduction
Antipseudomonal carbapenems have proven to be valuable in
the treatment of serious Gram-negative and polymicrobial
mixed aerobic and anaerobic infections. In their two-decade
history, imipenem and meropenem have primarily been used
to treat intractable, severe infections. Although relatively rare
at present, microbial resistance to carbapenems has reached
clinically important levels for several organisms, including
Pseudomonas aeruginosa, Acinetobacter spp.,  Klebsiella
spp., and Escherichia coli. Carbapenem resistance can have
a devastating impact because these agents often act as the
last line of defense against resistant organisms.
It is increasingly clear that the clinical efficacy of carba-
penems, particularly imipenem and meropenem, is critically
dependent on optimal dosing, especially in intensive care
units (ICUs), burn units, and extended care facilities where
multiresistant organisms are frequently encountered. Empiric
treatment to cover multiresistant pathogens may necessitate
using regimens at the higher end of the dosage range;
however, the use of such high doses may be problematic in
practice. For imipenem, the dose-dependent risk of neuro-
toxicity and seizure adverse events has led to recommen-
dations for caution in using high-dose regimens [1-4]. Similar
concerns may apply to meropenem, which has also been
associated with an increased seizure risk [3,5-7]. Higher
doses of carbapenems generally come at higher acquisition
costs, while use of lower doses may increase the risk of treat-
ment failure. Furthermore, suboptimal dosing is a well known
driver for the development of antibiotic resistance during
antibiotic therapy [8]. Appropriate dosing therefore presents
a serious therapeutic dilemma for clinicians who prescribe
carbapenems as empiric treatment for seriously ill patients.
This article explores the clinical impact of the relationship
between carbapenem dosing and adverse event risks,
pharmacodynamic-based dosing, and costs. It focuses on
imipenem, meropenem, and doripenem, as they are more
commonly used as empiric treatments for seriously ill patients
in settings such as the ICU [9]. Ertapenem has not been
discussed in this context because its lack of activity against
P. aeruginosa and Acinetobacter spp. typically precludes its
consideration for such cases [9]. Finally, it offers solutions to
address this growing public health concern.
Clinical roles of antipseudomonal
carbapenems
An analysis of data from the National Nosocomial Infections
Surveillance system between 1986 and 2003 examined
trends in the epidemiology of Gram-negative infections in
ICUs [10]. While overall percentages of Gram-negative
infections in ICU-treated pneumonias, surgical site infections,
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urinary tract infections, and bloodstream infections either
remained similar or declined, significant increases were seen
in infections caused by cephalosporin-resistant E. coli and
Klebsiella pneumoniae (related to extended spectrum
β-lactamase (ESBL)-producing strains), ceftazidime-resistant
P. aeruginosa, imipenem-resistant P. aeruginosa, and isolates
of Acinetobacter spp. resistant to amikacin, ceftazidime, or
imipenem. The authors concluded that increase in the preva-
lence of multidrug resistance - usually defined as resistance
to three or more of the antimicrobial agents antipseudomonal
penicillins, antipseudomonal cephalosporins, fluoroquino-
lones, carbapenems, and the aminoglycosides [11,12] - may
be the greatest concern for Gram-negative bacilli associated
with hospital-acquired infections [10].
Antipseudomonal carbapenems - imipenem, meropenem and
doripenem - have excellent activity against most strains of
many bacterial species and are regarded as safe and
generally well-tolerated. Because of their broad spectrum, the
antipseudomonal carbapenems are often effective against
organisms resistant to other antimicrobial agents and are
frequently used as empiric therapy in the ICU for polymicro-
bial infections. Of note, these carbapenems are resistant to
ESBLs, and so are of value in treating infections caused by
ESBL-producing strains of Enterobacteriaceae. Antipseudo-
monal carbapenems are indicated for a variety of hospital-
treated infections, including intra-abdominal, urinary tract, and
skin and skin structure infections. They are prescribed by
hospitalists, surgeons, intensivists, wound care specialists,
and infectious disease physicians in ICUs, postoperative
surgical units, burn units, and long-term care facilities. This
use may not always adhere to manufacturer-specific dosage
and prescribing practices aimed at minimizing the develop-
ment of carbapenem resistance in an effective manner.
In addition to empiric use of carbapenems, the use of this
class for surgical prophylaxis has been proposed. While a
recent study found a single prophylactic dose of ertapenem
superior to cefotetan in colorectal surgery [13], the use of
carbapenems for surgical prophylaxis remains controversial
[13-16], and in the absence of more evidence favoring carba-
penems for surgical prophylaxis, they are not recommended
for use in this setting.
Carbapenem dosing and seizure risk
Multiple studies have found that imipenem and meropenem
are associated with a dose-related increase in the risk for
seizure events [3,4,17-25]. The mechanism is not fully
understood [3,26,27]. Table 1 summarizes the range of
seizure rates reported with either imipenem or meropenem.
In the largest report on seizures during imipenem treatment,
underlying central nervous system disorders were common
among patients who experienced seizures [17]. In this study,
seizures occurred in 1.5% (37/2,516) of patients, although
only 0.24% (6/2,516) were considered to be imipenem-
related. A more recent study found no increase in seizure risk
for patients treated with imipenem at a maximum dose of
2 mg/day [3].
The risk of seizures with meropenem is widely believed to be
lower than with imipenem [26], but the evidence is not defini-
tive [3,6]. During clinical investigations, the overall seizure
rate in meropenem-treated patients was 0.7% (20/2,904)
[28], similar to the rate of 0.8% found in non-meningitis
patients treated with meropenem [29]. Doripenem does not
appear to have proconvulsive activity [30]. After more than a
year in clinical use, there are no reports of doripenem-related
seizures.
Although imipenem- or meropenem-related seizures are
usually reversible on discontinuation and are manageable
with anticonvulsants, the risk has made clinicians cautious
about using these drugs at high doses, and this caution may
be associated with the setting of upper limits on the dosing
window for these carbapenems that are sub-therapeutic.
Carbapenem dosing and pharmacodynamic
considerations
Imipenem, meropenem, and doripenem have elimination half-
lives of approximately 1 hour [1,28,31]. Like other β-lactams,
carbapenems have time-dependent bactericidal activity that
results from avid binding to penicillin-binding proteins and
disruption of bacterial cell wall synthesis. Carbapenems are
highly resistant to most β-lactamases, including ESBLs [32].
The key pharmacodynamic parameter is the time during
which the carbapenem concentration exceeds the minimum
inhibitory concentration (T>MIC), which should be at least
20% of the dosing interval for bacteriostatic effect and 40%
for maximum killing effect [33,34].
Dosing of carbapenems in the clinical setting must be
carefully judged to give the best chance of meeting or
exceeding the pharmacodynamic bactericidal T>MIC target
of 40%. Critical factors to take into account must include the
severity of infection, patient-specific pharmacokinetic considera-
tions and their impact on the drug concentration curve over
time, and an assessment of the most likely causative
pathogens. As carbapenems are often given empirically,
judgments on this last point should be made based on local
experience and on local antibiogram trends. When dealing
with seriously ill patients, the possible presence of
P. aeruginosa or Acinetobacter spp. should be considered, in
addition to resistant strains of Enterobacteriaceae (for
example, ESBL-producing strains). The potentially higher MIC
values associated with these species or strains will be a
factor in carbapenem selection and in the appropriate dosing
of the chosen carbapenem to ensure achievement of the
T>MIC target for these difficult-to-treat organisms [35].
Ideally, to help prevent the risk of under- or overdosing,
clinicians who can obtain carbapenem serum levels may
consider doing so in ICU patients.Page 3 of 10
(page number not for citation purposes)
Carbapenem dosing and efficacy
Carbapenems such as imipenem and meropenem have a
relatively narrow therapeutic window. The upper limit of this
window is bounded by the dose-dependent risk of seizure
adverse events, while the lower limit is set by pharmaco-
dynamics. Carbapenems require a T>MIC of at least 40% of
their dosing interval for maximal bactericidal activity, and
attainment of this pharmacodynamic target depends on
dosage, individual patient pharmacokinetics, and the MIC of
the target pathogen.
Several studies suggest that low doses of some carba-
penems are associated with decreased efficacy as reflected
in failure of cure, relapse, and superinfections, especially
when the infection involves species with high levels of
resistance (for example, high percentage of pseudomonal
isolates with MICs >4), such as P. aeruginosa. In patients
with soft tissue infections, a 2 g/day regimen of imipenem
provided a response rate of 95% (56% clinical cure, 38%
improvement). Rates of microbiologic eradication ranged
from 61% for P. aeruginosa to 100% for anaerobic bacteria
[36]. In patients with febrile neutropenia, a study using the
2 g/day imipenem regimen reported a 77% response rate
[37]. In patients with intra-abdominal infections, reported cure
rates at the 2 g/day dosage range from 76% to 81% [38-40],
and at a lower dosage (1.5 g/day in three 500-mg infusions
8 hours apart), the cure rate was 69% [41]. In the absence of
controlled trials comparing different imipenem doses, these
Available online http://ccforum.com/content/12/5/233
Table 1
Summary of selected reports of seizure adverse events in patients receiving imipenem or meropenem
Study Patient population Dosage Seizure incidence Notes
Imipenem
Winston et al.  35 patients with infections  4 g/day (23 patients);  None
1984 [24] from imipenem-susceptible  <4 g/day (12 patients)
organisms
Calandra et al.  First 2,516 patients treated;  <2 g/day, 32 percent;  1.5 percent (37/2,516) all  High rates of central 
1985 [17] most had significant  2 g/day, 44 percent;  episodes; 0.24 percent  nervous system disorders 
background disorders >2 g/day, 24 percent (6/2,516) imipenem related in patients with seizures
Winston et al.  29 febrile granulocytopenic  1 g q6h 10.3 percent (3/29) Versus 0 percent (0/58) 
1988 [25] patients treated with 2 β-lactams
Eng et al.  First 22 patients treated  Varied (500 mg q12h to  22.7 percent (5/22) 
1989 [4] 1 g q6h)
Rolston et al.  371 febrile neutropenic  12.5 mg/kg q6h 1.5 percent (3/196) imipenem +  1 g qh6 for an 80 kg 
1992 [22] cancer patients vancomycin; 3.4 percent (6/175) patient
imipenem + amikacin
Norrby et al.  197 patients with severe  500 mg q6h adjusted for  0.5 percent (1/197) Versus 0 percent (0/196) 
1993 [19] nosocomial infections renal dysfunction treated with ceftazidime
Raad et al.  198 febrile neutropenic  500 mg q6h 0.5 percent (1/198) imipenem +  Versus 0 percent (0/192) 
1996 [21] cancer patients vancomycin treated with aztreonam + 
vancomycin
Karadeniz et al.  82 pediatric patients with  50 mg/kg/day in 3 doses 3.6 percent (3/82)
2000 [18] malignancies
Koppel et al.  98 patients Max. 2 g/day 4.0/1,000 patient-days (on  No increase in risk due to 
2001 [3] imipenem); 3.9/1,000 patient- imipenem
days (not on imipenem)
Winston et al.  541 febrile granulocyto- 500 mg q6h 2 percent 0 percent for clinafloxacin 
2001 [94] penic patients (200 mg every 12 h); 
P = 0.06
Meropenem
Sieger et al.  104 patients with noso- 1 g q8h 2.9 percent (3/104) all 
1997 [96] comial lower respiratory  episodes; 0 percent 
tract infections meropenem related
Norrby et al.  4,872 patients in multiple  0.5 to 1 g q8h Meropenem related: 0.08 percent 
1999 [29] trials (patients without meningitis); 
0 percent (patients with meningitis)data suggest that imipenem 2 g/day, which minimizes the
incidence of seizure adverse events, may be less effective
than 4 g/day. Thus, the need for a relatively low dose of imi-
penem to avoid seizure adverse events may offset its
potential antimicrobial activity [4].
Kuti and colleagues [42] performed a Monte Carlo analysis to
evaluate the probability of a 500 mg/6 hour dosing regimen
of meropenem and imipenem to attain three different pharma-
codynamic targets over the entire dosing interval (T>MIC
30%, T>MIC 50%, and T>MIC 100%) for different patho-
gens. Probabilities of staying above the MIC target
throughout the dosing interval were similar between the two
agents for T>MIC 30% or T>MIC 50% (Table 2). Figure 1
shows the probability of attaining the dosing targets across a
range of MIC values, and while the differences are statistically
significant, this calculation does not take into account protein
binding differences that affect drug availability, reducing the
accuracy of the findings, so the clinical significance is not
clear [42]. Nevertheless, the model demonstrates the impor-
tance and complexities involved in delivering drugs effec-
tively, taking into account pharmacodynamic properties.
Carbapenem resistance
Levels of resistance have increased considerably since the
introduction of the first carbapenem, particularly among
Gram-negative organisms [43]. Carbapenem resistance
among A. baumannii and P. aeruginosa is a pressing prob-
lem [2,24,44-55] with steady increases in the prevalence and
geographic spread of carbapenem-resistant strains [56-58],
and reported rates of resistance as high as 16.3% worldwide.
In North America, rates of 3.1% for P. aeruginosa [59] and
3.2% for Acinetobacter spp. [60] have been reported.
Between 1997 and 1999 and 2004 and 2006, imipenem
nonsusceptibility in P. aeruginosa increased from 23.6% to
29.3% and from 33.3% to 47.5% in Acinetobacter spp. [43].
Resistance in K. pneumoniae has also been reported [61].
For 2004 and 2005, meropenem nonsusceptibility for
P. aeruginosa was 9.7% and 12.4%, respectively, and for
Acinetobacter spp. was 23.9% and 14.4%, respectively [62].
Three mechanisms for carbapenem resistance development
have been identified: reduced carbapenem influx due to
changes in expression of outer membrane porins [63],
Critical Care    Vol 12 No 5 Slama
Page 4 of 10
(page number not for citation purposes)
Table 2
Probability of meropenem and imipenem attaining pharmacodynamic targets over entire dosing interval for 30, 50, and 100
percent T>MIC for selected bacterial populations [42]
Pharmacodynamic target for entire dosing interval
30 percent T>MIC 50 percent T>MIC 100 percent T>MIC
Species Meropenem Imipenem Meropenem Imipenem Meropenem Imipenem
Escherichia coli 100 100 100 100 100 94
Klebsiella pneumoniae 100 100 99 100 99 91
Enterobacter cloacae 100 100 100 100 95 71
Serratia marcescens 99 99 99 99 97 57
Acinetobacter baumannii 83 89 79 88 31 60
Pseudomonas aeruginosa 93 92 87 87 47 27
T>MIC, time greater than minimum inhibitory concentration.
Figure 1
Probability of attaining pharmacodynamic target during entire dosing
interval (T>MIC >30%, 50%, and 100%) as a function of MIC for
imipenem and meropenem at a dosage of 500 mg q6h. The 30% and
50% targets represent conservative estimates for bacteriostatic and
bactericidal activity, respectively. Each curve shows the likelihood of
the drug to stay above the target MIC for the entire dosing period
based on the pathogen’s MIC. Note the steep declines in probabilities
for MIC values between 0.5 and 4. Reproduced with permission from
Kuti et al. [42].secretion of carbapenemases [44,61,63,64], and efflux pump
production [65]. Studies have suggested that resistance to
imipenem may occur through a loss of porin expression alone,
whereas with meropenem and doripenem the combination of
porin loss together with increased efflux pump production is
required to confer resistance [66-68].
Carbapenemases affect all three antipseudomonal
carbapenems. At present they are relatively rare in the US;
however, carbapenemases are a source for future concern as
they inactivate not just carbapenems but virtually all β-lactam
based antibacterials. Furthermore, detection of carbapene-
mases is not well-addressed by current automated testing
systems. One study found that clinical laboratory testing mis-
identified approximately 15% of carbapenemase-producing
K. pneumoniae strains as imipenem-susceptible [69]. A
second study evaluated several automated test systems for
detection of carbapenem resistance in 15 strains previously
identified by broth microdilution as non-susceptible to
imipenem and meropenem [70]. Depending on the test
system used, between 1 and 13 of the 15 nonsusceptible
strains were misidentified as susceptible. Although several
methods for assessing carbapenemase production have
been proposed [71-74], current guidelines do not include
protocols for assaying carbapenemase production.
Imipenem and other carbapenems are considered the most
effective available agents for treating Acinetobacter infections
[75,76]. However, A. baumannii strains with high-level carba-
penem resistance have become widespread [44]. Carbapenem-
resistant  A. baumannii has been reported worldwide, with
outbreaks in the United States [51], Europe [45,49,54],
South America [47], and Asia [50,53]. A recent Turkish study
of patients with postneurosurgical meningitis found that 45%
of 29 infections due to Acinetobacter spp. were imipenem-
resistant before the initiation of therapy [52].
Carbapenem dosing and resistance
Resistance to carbapenems probably reflects two major
drivers: the 20-year history of widespread use of imipenem
and other carbapenems, and dosing that is suboptimal for
pathogens with higher MICs, including intermediate and
resistant organisms.
The general association between antibiotic use and antibiotic
resistance is well known and believed to be causal [77].
Several reports exemplify this linkage for carbapenems. A
study in a 600-bed community hospital found a strong
association between imipenem usage and resistance in
P. aeruginosa (Figure 2), although it is unclear whether the
strain was treated adequately or if infection control
techniques were uniformly adopted [78]. In another study, an
attempt to prevent cephalosporin resistance by decreasing
cephalosporin use caused a compensatory 140.6% increase
in carbapenem use and an increase of 68.7% in the preva-
lence of imipenem-resistant P. aeruginosa infections [79].
Similarly, a Polish pediatric hospital in which carbapenem use
quadrupled between 1993 and 2002 found that the
percentage of isolates susceptible to imipenem decreased
from 95.7% to 81.7%, and that MIC90 increased from
2 mg/dL to 16 mg/dL over the same period (Figure 3) [80].
Suboptimal dosing is a well known driver for the development
of antibiotic resistance during antibiotic therapy [8]. As
already noted, optimal bactericidal dosing for carbapenems
requires maintaining drug levels so that T>MIC exceeds
40% of the dosing interval [26,81,82]. The standard 500 mg
q6h regimen for imipenem/cilastatin meets this criterion in
healthy individuals for susceptible pathogens. However, as
shown in Figure 4, the 500 mg q6h regimen provides T>MIC
values of 38% and 23%, respectively, for organisms with 1.5
to 3.0 mg/dL and 3 to 6 mg/dL MIC values [83]. Thus, the
500 mg q6h regimen and lower dosages may not be
adequate for pathogens with a MIC >1.5 mg/dL.
Also of concern is the emergence of resistance during a
course of carbapenem therapy. Fink and colleagues [48]
investigated imipenem 3 g/day (1,000 mg q8h) in 200 patients
with severe pneumonia. Microbiologic eradication occurred in
59% of the imipenem-treated patients. A total of 44 different
strains of P. aeruginosa were isolated from 32 of these
patients, and 50% of these strains developed imipenem
resistance during the trial. More recently, in a study of
nosocomial pneumonia, resistance developed in 33% (nine of
27) of patients with P. aeruginosa infections during treatment
with imipenem 500 mg q6h. Resistance was present at the
start of therapy in 5 of 32 (16%) patients (5 patients in this
group were excluded after randomization) [55]. Use of
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Figure 2
Correlation between imipenem usage and imipenem resistance in
P. aeruginosa in a community hospital. DDD, defined daily dose.
Reproduced with permission from [78].imipenem as monotherapy to treat P. aeruginosa is not
recommended because, as the examples above show,
imipenem monotherapy is associated with considerable risk
for P. aeruginosa resistance [84,85].
Intermediate susceptibility to imipenem is common among
P. aeruginosa strains, and imipenem 500 mg q6h is
frequently unable to achieve a sufficient T>MIC for effective
eradication. In a trial comparing imipenem/cilastatin with
ceftazidime for serious nosocomial infections, P. aeruginosa
infections resolved in only 8 of 19 patients treated with
imipenem, compared with 14 of 17 infections in patients
treated with ceftazidime (P = 0.004); resistance developed in
6 of 19 and 1 of 17 patients, respectively [19].
Altered carbapenem T>MIC values in an individual patient
may also reflect the presence of severe illness, which can
affect any pharmacokinetic parameter of a drug [81,86].
Regimens that do not account for these conditions may not
maintain antibiotic levels sufficient for eradication [86]. One
example is patients who are anuric or receiving continuous
renal replacement therapy. Current continuous renal replace-
ment therapy techniques provide rapid systemic drug
clearance, and carbapenem regimens that are not adjusted
accordingly may result in suboptimal drug levels, ineffective
eradication, and an increased likelihood of resistance [81].
Overall, these considerations suggest that standard carba-
penem dosages (for example, imipenem 2 g/day) may be
suboptimal in terms of microbiologic eradication and
resistance development for some infections in some patients,
particularly pathogens with intermediate susceptibility and
patients with altered pharmacokinetic properties when doses
are not adjusted appropriately.
Clinical implications
The increasing prevalence of carbapenem resistance has
broad and significant clinical implications because mortality
and the cost of care are significantly increased in patients with
carbapenem-resistant infections. Mortality in patients with
carbapenem-resistant infections is approximately twice that of
patients with carbapenem-susceptible infections: Kwon and
colleagues [87] reported mortality rates of 57% and 27.5%,
respectively, in patients with imipenem-resistant and imipenem-
susceptible  Acinetobacter bacteremia (relative risk 30-day
mortality was 2.019 (95% confidence interval, 1.18 to 3.69;
P = 0.007). The primary risk factor for mortality was the use of
discordant antimicrobial therapy, that is, when the pathogen
was not susceptible to any agent in the antimicrobial regimen
[87]. Studies of multidrug-resistant (MDR) P. aeruginosa
infections report an odds ratio for mortality of 15.13 (95%
confidence interval, 1.90 to 323.13; P = 0.001) for MDR
versus susceptible infections in patients with P. aeruginosa
bacteremia [88], and hospital costs for MDR and susceptible
infections of $54,081 and $22,116, respectively [89].
In addition, resistance can be transmitted and consequently
lead to outbreaks of carbapenem-resistant infections.
Critical Care    Vol 12 No 5 Slama
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Figure 3
Imipenem susceptibility and carbapenem use at a Polish pediatric
hospital (1993 to 2002). DDD, defined daily dose. Reprinted from
Patzer and Dzierzanowska [80], with permission from Elsevier.
Figure 4
Effect of imipenem dose on the time during which serum imipenem
exceeds the MIC90 in healthy volunteers after a 30 minute infusion
[83]. The dashed line shows the percentage of the dosing cycle
required for optimal dosing.Mikolajczyk and colleagues [90] estimated that 45% of
imipenem-resistant  P. aeruginosa infections result from
transmission. Multiple outbreaks of carbapenem-resistant A.
baumannii and P. aeruginosa have been reported, including a
major citywide outbreak that occurred in 15 Brooklyn, NY
hospitals in 1999. During the outbreak, carbapenem resis-
tance was found in 53% of A. baumannii isolates and 24% of
P. aeruginosa isolates. Approximately 400 patients were
infected or colonized with a carbapenem-resistant strain [91].
Multidrug-resistant A. baumannii and P. aeruginosa are now
endemic in the New York area, and the production of carba-
penemases is increasingly common in K. pneumoniae and
E. coli [56,58,69].
The increasing prevalence of imipenem resistance may also
affect dosing requirements. In the past, before the emer-
gence of MDR organisms became a common problem, the
clinical impact of regimens using low imipenem dosages was
relatively minor. With the emergence of MDR P. aeruginosa
and  Acinetobacter spp., inadequate dosing is increasingly
likely to affect outcomes.
Although it is possible to prevent and control these outbreaks
using a variety of measures such as patient screening and
isolation, resistance monitoring, and infection control proce-
dures, it is prudent to take measures to prevent or slow the
development of carbapenem resistance.
Possible approaches to managing the problem include the
use of novel dosing regimens, including extended infusions
[92-94] and the use of novel or alternative antibiotic agents.
Regimens using longer infusion times may help ensure that
drug levels are maintained above the MIC90 for at least 40%
of the dosing interval. Alternative antibiotic agents could
include novel agents, carbapenems or other agents, and
combination therapies. Alternative agents can be evaluated
by the criteria put forth by the Council for Appropriate and
Rational Antibiotic Therapy (CARAT). These criteria include
the strength of evidence supporting the use of the antibiotic,
the expected therapeutic benefits and the possibility of
resistance, the adverse-event profile, the cost-effectiveness
of therapy with the agent, and the appropriate dosage and
duration [95]. Cost-containment strategies may have to be
adjusted to maintain adequate carbapenem dosing. Greater
awareness and education regarding MDR pathogens and
carbapenem treatment issues across hospital departments
remains a vital need.
Conclusion
Imipenem and meropenem have been a useful part of the
antimicrobial armamentarium for 20 and 10 years, respec-
tively, and continue as valuable agents for treatment of Gram-
negative infections. However, they have a narrow therapeutic
window and the need for low-dose therapy to avoid
neurotoxicity and the need for high-dose therapy to ensure
efficacy and prevent the development of resistance are in
constant conflict. It is not yet clear whether an optimal
antimicrobial dosage is attainable, given the seizure risk, or a
suboptimal dosage acceptable, given the risks for treatment
failure and resistance development. While avoidance of
seizure adverse events may limit dosages - for example,
imipenem 2 g/day or less (adjusted as necessary for renal
dysfunction and other conditions) - these dosages are likely
to be suboptimal for treatment of infections involving P.
aeruginosa, A. baumannii, and other organisms with
intermediate susceptibility. Underdosing may well decrease
the efficacy of therapy while increasing the probability of
resistance development.
Solutions include increasing awareness of treating resistant
organisms, utilizing optimal dosing regimens in areas of the
hospital where multiresistant organisms are more likely en-
countered, using alternative antimicrobials with more favorable
pharmacokinetics, pharmacodynamics, and adverse-event
profiles, and using newer carbapenems with lower propensity
for resistance development (for example, reduced expression
of efflux pumps or greater stability against carbapenemases).
Achieving success requires hospital systems and physicians
to continue to work together to create clinical solutions that
optimize patient care.
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